Access Industries-backed Acelyrin filed to go public while Lockheed Martin took part in Orbit Fab’s $28.5m series A round.
Public markets Acelyrin, a US-based inflammatory disorder drug developer backed by industrial conglomerate Access Industries, filed to raise $100m in an initial public offering on the Nasdaq Global Market. It has received a total of $408m in venture funding, and the corporate’s Access Biotechnology unit owns a 3.9% stake having led a $300m series C…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
